查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1159353

卵巢癌症治疗药的全球市场(2022年～2028年)

Ovarian Cancer Drugs Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 125 Pages | 商品交期: 2-3个工作天内

价格

全球卵巢癌症治疗药的市场规模，在预测期间内预计以13.8％大幅度的年复合成长率成长。卵巢癌症治疗的认识高涨，和新兴国家的医疗费增加，推动卵巢癌症治疗药市场成长。医疗费增加，使许多人能利用先进的医疗设施，进而推动含卵巢癌症的各种癌症的诊断和治疗。

本报告提供全球卵巢癌症治疗药市场相关调查，市场概要，以及竞争情形，各市场区隔的市场，各地区分析，及企业简介等资讯。

目录

第1章 报告概要

第2章 市场概要与考察

  • 调查范围
  • 分析师的考察和目前市场趋势

第3章 竞争情形

  • 主要企业分析
  • AstraZeneca PLC
  • Clovis Oncology, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • 主要策略分析
  • COVID-19对主要企业的影响

第4章 市场区隔

  • 全球卵巢癌症治疗药市场:各类药物
    • PARP抑制剂
    • 血管新生抑制剂
    • PD-L1抑制剂
  • 全球卵巢癌症治疗药市场:各治疗法
    • 化疗
    • 标靶治疗
    • 免疫疗法
    • 其他(荷尔蒙疗法)

第5章 地区分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 全球其他地区

第6章 企业简介

  • Amgen Inc.
  • AbbVie Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • DelMar Pharmaceuticals, Inc.
  • Eli Lilly and Co.
  • Exelixis, Inc.
  • Genentech, Inc.
  • ImmunoGen Inc.
  • Janssen Global Services, LLC (Johnson & Johnson Services, Inc的部门)
  • Mersana Therapeutics, Inc.
  • Oasmia Pharmaceutical AB
  • OncBioMune Pharmaceuticals Inc.
  • Pfizer Inc.
Product Code: OMR2026476

Global Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report by Drug Class (PARP Inhibitors, Angiogenesis Inhibitors, PD-L1 Inhibitors), and by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, and Others) Forecast Period (2022-2028)

The global ovarian cancer drugs market is anticipated to grow at a substantial CAGR of 13.8% during the forecast period. The rising awareness towards the ovarian cancer treatment along with increase in healthcare expenditure in emerging economies is propelling the growth of ovarian cancer drugs market. The increase in expenditure on healthcare is mainly supported by the need among individuals for quality healthcare services. According to the statistics by the World Bank, the current health expenditure (% of GDP) around the world increased from 8.63% in 2000 to 9.84% in 2019. Rising healthcare expenditure is allowing a large number of people to access advanced healthcare facilities, which in turn, is contributing to the diagnosis and treatment of various cancers, including ovarian cancer.

The global Ovarian Cancer Drugs market is segmented based on the drug class, and therapy. Based on the drug class, the market is segmented into PARP inhibitors, angiogenesis inhibitors, and PD-L1 inhibitors. Based on, the therapy the market is sub-segmented into the chemotherapy, targeted therapy, immunotherapy, and others. The above-mentioned segments can be customized as per the requirements. On the basis of drug class, PARP inhibitors are anticipated to be the fastest growing drug class in the ovarian cancer market owing to increasing research and development among major key players to develop new products is anticipated to drive the growth of the market. For instance, in April 2020, the US Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Furthermore, other factors such as increase in demand for PARP inhibitors due to their superior efficacy are likely to boost further market growth.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Asia-Pacific is estimated to contribute significantly to the growth of the market. China and India are the major contributors to the growth of the Asia-Pacific ovarian cancer drugs market. The high prevalence and incidence rate of ovarian cancer in China, augments the adoption of drugs and devices for the treatment of ovarian cancer, marking it one of the key factors that drive the market growth. The rising healthcare industry and cancer research institutes along with increasing awareness regarding the treatment procedures of ovarian cancer is further propelling market growth. Additionally, Asia-Pacific comprises approximately 60% of the world population, the region accounts to register a significant proportion in total cases of cancer every year, owing to which, the market for ovarian cancer drugs is growing proportionally in Asia-Pacific.

The major companies serving the global Ovarian Cancer Drugs market include AstraZeneca PLC, Clovis Oncology, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In 2020, AstraZeneca and MSD Inc announced that Lynparza*(Olaparib) in combination with bevacizumab has been approved in the US for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Research Methodology

The market study of the global ovarian cancer drugs market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Ovarian Cancer Drugs Market Research and Analysis by Drug Class.

2. Global Ovarian Cancer Drugs Market Research and Analysis by Therapy.

The Report Covers:

  • Comprehensive Research Methodology of the global ovarian cancer drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global ovarian cancer drugs market.
  • Insights about market determinants that are stimulating the global ovarian cancer drugs market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Ovarian Cancer Drugs Market
  • Recovery Scenario of Global Ovarian Cancer Drugs Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. AstraZeneca PLC
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Clovis Oncology, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. F. Hoffmann-La Roche Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. GlaxoSmithKline PLC
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Merck & Co., Inc.
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis
  • 3.8. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Ovarian Cancer Drugs Market by Drug Class
    • 4.1.1. PARP Inhibitors
    • 4.1.2. Angiogenesis Inhibitors
    • 4.1.3. PD-L1 Inhibitors
  • 4.2. Global Ovarian Cancer Drugs Market by Therapy
    • 4.2.1. Chemotherapy
    • 4.2.2. Targeted Therapy
    • 4.2.3. Immunotherapy
    • 4.2.4. Others (Hormonal Therapy)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Amgen Inc.
  • 6.2. AbbVie Inc.
  • 6.3. Boehringer Ingelheim GmbH
  • 6.4. Bristol-Myers Squibb Co.
  • 6.5. DelMar Pharmaceuticals, Inc.
  • 6.6. Eli Lilly and Co.
  • 6.7. Exelixis, Inc.
  • 6.8. Genentech, Inc.
  • 6.9. ImmunoGen Inc.
  • 6.10. Janssen Global Services, LLC, a division of Johnson & Johnson Services, Inc,
  • 6.11. Mersana Therapeutics, Inc.
  • 6.12. Oasmia Pharmaceutical AB
  • 6.13. OncBioMune Pharmaceuticals Inc.
  • 6.14. Pfizer Inc.

LIST OF TABLES

  • 1. GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 2. GLOBAL PARP INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL ANGIOGENESIS INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL PD-L1 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
  • 6. GLOBALOVARIAN CANCER DRUGS IN CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL OVARIAN CANCER DRUGS IN TARGETED THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL OVARIAN CANCER DRUGS IN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL OVARIAN CANCER DRUGS IN OTHER THERAPIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 11. NORTH AMERICAN OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
  • 14. EUROPEAN OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 15. EUROPEAN OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 16. EUROPEAN OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
  • 17. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
  • 20. REST OF THE WORLD OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL OVARIAN CANCER DRUGS MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL OVARIAN CANCER DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL OVARIAN CANCER DRUGS MARKET, 2022-2028 (%)
  • 4. GLOBAL OVARIAN CANCER DRUGS MARKET SHARE BY DRUG CLASS, 2021 VS 2028 (%)
  • 5. GLOBAL PARP INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL ANGIOGENESIS INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL PD-L1 INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL OVARIAN CANCER DRUGS MARKET SHARE BY THERAPY, 2021 VS 2028 (%)
  • 9. GLOBAL OVARIAN CANCER DRUGS IN CHEMOTHERAPY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL OVARIAN CANCER DRUGS IN TARGETED THERAPYMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL OVARIAN CANCER DRUGS IN IMMUNOTHERAPYMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL OVARIAN CANCER DRUGS IN OTHER THERAPIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL OVARIAN CANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. US OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. CANADA OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. UK OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. ITALY OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. REST OF EUROPE OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. INDIA OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. CHINA OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. REST OF ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF THE WORLD OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)